Astellas and Cytokinetics expand accord on skeletal muscle activators

26 December 2014
2019_biotech_test_vial_discovery_big

US biotech firm Cytokinetics (Nasdaq: CYTK) and Japanese pharma major Astellas Pharma (TYO: 4503) have amended their collaboration agreement focused on the research, development and commercialization of skeletal muscle activators.

Shares of Cytokinetics jumped as much as 12.7% following the news on December 24, but closed the holiday-shortened trading day up 6.3% at $5.87.

The companies have been jointly conducting R&D activities with the objective to advance novel skeletal sarcomere targeted therapies for diseases and medical conditions associated with muscle weakness in non-neuromuscular indications. The collaboration has been expanded to enable development of CK-2127107, a fast skeletal troponin activator, in spinal muscular atrophy (SMA) and potentially other neuromuscular indications.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology